Literature DB >> 19234869

The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy.

Isis Gayed1, Salman Gohar, Zhongxing Liao, Mary McAleer, Roland Bassett, Syed Wamique Yusuf.   

Abstract

PURPOSE: This study aims to identify the clinical implications of myocardial perfusion defects after chemoradiation therapy (CRT) in patients with esophageal and lung cancer.
METHODS: We retrospectively compared myocardial perfusion imaging (MPI) results before and after CRT in 16 patients with esophageal cancer and 24 patients with lung cancer. New MPI defects in the radiation therapy (RT) fields were considered related to RT. Follow-up to evaluate for cardiac complications and their relation with the results of MPI was performed. Statistical analysis identified predictors of cardiac morbidities.
RESULTS: Eleven females and twenty nine males at a mean age of 66.7 years were included. Five patients (31%) with esophageal cancer and seven patients (29%) with lung cancer developed myocardial ischemia in the RT field at mean intervals of 7.0 and 8.4 months after RT. The patients were followed-up for mean intervals of 15 and 23 months in the esophageal and lung cancer groups, respectively. Seven patients in each of the esophageal (44%) and lung (29%) cancer patients (P = 0.5) developed cardiac complications of which one patient with esophageal cancer died of complete heart block. Six out of the fourteen patients (43%) with cardiac complication had new ischemia on MPI after CRT of which only one developed angina. The remaining eight patients with cardiac complications had normal MPI results. MPI result was not a statistically significant predictor of future cardiac complications after CRT. A history of congestive heart failure (CHF) (P = 0.003) or arrhythmia (P = 0.003) is a significant predictor of cardiac morbidity after CRT in univariate analysis but marginal predictors when multivariate analysis was performed (P = 0.06 and 0.06 for CHF and arrhythmia, respectively).
CONCLUSIONS: Cardiac complications after CRT are more common in esophageal than lung cancer patients but the difference is not statistically significant. MPI abnormalities are frequently seen after CRT but are not predictive of future cardiac complications. A history of arrhythmia or CHF is significantly associated with cardiac complications after CRT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234869     DOI: 10.1007/s10554-009-9440-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  26 in total

Review 1.  Cardiovascular sequelae of therapeutic thoracic radiation.

Authors:  M A Arsenian
Journal:  Prog Cardiovasc Dis       Date:  1991 Mar-Apr       Impact factor: 8.194

2.  Cardiac morbidity of adjuvant radiotherapy for breast cancer.

Authors:  Debra A Patt; James S Goodwin; Yong-Fang Kuo; Jean L Freeman; Dong D Zhang; Thomas A Buchholz; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

3.  Risk of cardiac death after adjuvant radiotherapy for breast cancer.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Jean L Freeman; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin
Journal:  J Natl Cancer Inst       Date:  2005-03-16       Impact factor: 13.506

4.  Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer.

Authors:  L E Rutqvist; I Lax; T Fornander; H Johansson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy.

Authors:  I HŁjris; N P Sand; J Andersen; M Rehling; M Overgaard
Journal:  Radiother Oncol       Date:  2000-05       Impact factor: 6.280

6.  Time dependent changes in myocardial norepinephrine concentration and adrenergic receptor density following X-irradiation of the rat heart.

Authors:  N A Franken; A van der Laarse; F J Bosker; I W Reynart; F J van Ravels; E Strootman; J Wondergem
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  Coronary artery disease mortality in patients treated for Hodgkin's disease.

Authors:  J F Boivin; G B Hutchison; J H Lubin; P Mauch
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

8.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.

Authors:  S L Hancock; M A Tucker; R T Hoppe
Journal:  JAMA       Date:  1993-10-27       Impact factor: 56.272

9.  Radiotherapy as a cause of complete atrioventricular block in Hodgkin's disease. An electrophysiological-pathological correlation.

Authors:  S I Cohen; S Bharati; J Glass; M Lev
Journal:  Arch Intern Med       Date:  1981-04

10.  Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.

Authors:  David K Espey; Xiao-Cheng Wu; Judith Swan; Charles Wiggins; Melissa A Jim; Elizabeth Ward; Phyllis A Wingo; Holly L Howe; Lynn A G Ries; Barry A Miller; Ahmedin Jemal; Faruque Ahmed; Nathaniel Cobb; Judith S Kaur; Brenda K Edwards
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

View more
  16 in total

1.  Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer.

Authors:  Steven H Lin; Ning Zhang; Joy Godby; Jingya Wang; Gary D Marsh; Zhongxing Liao; Ritsuko Komaki; Linus Ho; Wayne L Hofstetter; Stephen G Swisher; Reza J Mehran; Thomas A Buchholz; Linda S Elting; Sharon H Giordano
Journal:  Cancer       Date:  2015-12-30       Impact factor: 6.860

2.  Cardiac perfusion screening in patients to be treated with radiation therapy in the chest, is it a must?

Authors:  Leo H B Baur
Journal:  Int J Cardiovasc Imaging       Date:  2009-05-12       Impact factor: 2.357

3.  Increased risk of death due to heart disease after radiotherapy for esophageal cancer.

Authors:  Jonathan Frandsen; Dustin Boothe; David K Gaffney; Brent D Wilson; Shane Lloyd
Journal:  J Gastrointest Oncol       Date:  2015-10

4.  Volumetric modulated arc therapy planning for distal oesophageal malignancies.

Authors:  M A Hawkins; J L Bedford; A P Warrington; D M Tait
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

5.  Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Noriaki Iwahashi; Masami Kosuge; Kentaro Sakamaki; Chikara Kunisaki; Kazuo Kimura
Journal:  Strahlenther Onkol       Date:  2016-02-16       Impact factor: 3.621

6.  Radiation-induced heart disease: a clinical update.

Authors:  Syed Wamique Yusuf; Shehzad Sami; Iyad N Daher
Journal:  Cardiol Res Pract       Date:  2011-02-27       Impact factor: 1.866

Review 7.  Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods.

Authors:  Aaron Soufer; Chi Liu; Mariana L Henry; Lauren A Baldassarre
Journal:  J Nucl Cardiol       Date:  2019-03-13       Impact factor: 3.872

Review 8.  Radiation-induced heart disease in lung cancer radiotherapy: A dosimetric update.

Authors:  Xin Ming; Yuanming Feng; Chengwen Yang; Wei Wang; Ping Wang; Jun Deng
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

9.  Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database.

Authors:  Laila Gharzai; Vivek Verma; Kyle A Denniston; Abhijeet R Bhirud; Nathan R Bennion; Chi Lin
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

10.  Cardiac Exposure in the Dynamic Conformal Arc Therapy, Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy of Lung Cancer.

Authors:  Xin Ming; Yuanming Feng; Huan Liu; Ying Zhang; Li Zhou; Jun Deng
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.